-transparent.png){kind=logo}
The passage of 6-[(R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen), into the CSF was studied in 9 patients with symptoms of acute meningitis, presumed to be of viral origin. The antibiotic was given as a single 5 g dose i.v. over 30 min. The CSF/serum concentration ratio of mezlocillin showed a variation from 0 to 10.7%. The antibiotic could be effective in the treatment of bacterial meningitis caused by ampicillin-resistant strains of Haemophilus influenzae and by most Enterobacteriaceae, provided these results will be confirmed by a study now in progress. In one patient suffering from meningococcal meningitis this concentration ratio varied between 72% (day 3) and 54% (day 12).
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
May 1986,
The Japanese journal of antibiotics,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
January 1992,
Antibiotics and chemotherapy,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
January 2014,
Scandinavian journal of infectious diseases,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
June 1978,
Antimicrobial agents and chemotherapy,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
January 1993,
The Japanese journal of antibiotics,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
May 1981,
Drug intelligence & clinical pharmacy,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
August 1988,
The Journal of antimicrobial chemotherapy,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
November 2009,
Antimicrobial agents and chemotherapy,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
August 2004,
Anti-cancer drugs,
J Modai, and
J Pierre, and
E Bergogne-Berezin, and
M F Avril
April 1986,
European journal of clinical microbiology,
